Malignant Pleural Effusions Clinical Trial
Official title:
A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Pleural Effusions
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once via intrapleural injection (SAD) and once daily over 2 to 3 days (MAD)for the treatment of cancer patients with symptomatic malignant pleural effusions requiring drainage.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05543330 -
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT00758316 -
A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions
|
Phase 3 | |
| Enrolling by invitation |
NCT02092155 -
Biomarker Levels During Indwelling Pleural cAtheter Sample Testing
|
||
| Recruiting |
NCT00430664 -
A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis
|
N/A | |
| Completed |
NCT00188474 -
A Quality of Life Study re Management of Malignant Pleural Effusions
|
N/A | |
| Terminated |
NCT02623959 -
Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis
|
Phase 4 | |
| Completed |
NCT02227732 -
A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural Effusions
|
N/A |